Evidence map›Paper›PMID 27453733›Full record

ArticleDiabetology & metabolic syndrome2016

Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline data.

Bruno Linetzky, Brad Curtis, Gustavo Frechtel, Renan Montenegro, Miguel Escalante Pulido, Oded Stempa, Janaina Martins de Lana, Juan José Gagliardino

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Diabetology & metabolic syndrome, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01400971 (A Multinational Observational Study Assessing Insulin Use), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01400971 completednot on this map

A Multinational Observational Study Assessing Insulin Use: Understanding the Challenges Associated With Progression of Therapy - The MOSAIc Type 2 Diabetes Study

TypeobservationalSponsorEli Lilly and CompanyRan2011 to 2015Enrolled4,299ConditionsDiabetes Mellitus, Type 2
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Bruno LinetzkyEli Lilly and Company, Tronador 4890, Piso 12, CABA, C1430DNN Buenos Aires, Argentina.
Brad CurtisEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA.
Gustavo FrechtelServicio de Nutrición y Diabetes, Hospital Sirio Libanes, Campana 4658, C1419HN Buenos Aires, Argentina.
Renan MontenegroSchool of Medicine of the Federal University of Ceará, Rua Capitao Francisco Pedro, 1290 Fortaleza, Ceara, 60430-370 Brazil.
Miguel Escalante PulidoHospital de Especialidades del Centro Médico de Occidente IMSS, Belisario Domínguez 1000, piso 2., Col. Independencia Guadalajara, Jalisco, Mexico.
Oded StempaEli Lilly and Company, Barranca del Muerto 329-1, Col. San José Insurgentes, Delegación Benito Juárez, Mexico, 03900 Distrito Federal Mexico.
Janaina Martins de LanaEli Lilly and Company, Av. Morumbi 8.264, São Paulo, Brazil.
Juan José GagliardinoCENEXA, Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), Calle 60 y 120, La Plata, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas · AREli Lilly (United States) · USHospital de Especialidades · MXUniversidade Federal do Ceará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoor glycemic control in patients with type 2 diabetes is commonly recorded worldwide; Latin America (LA) is not an exception. Barriers to intensifying insulin therapy and which barriers are most likely to negatively impact outcomes are not completely known. The objective was to identify barriers to insulin progression in individuals with type 2 diabetes mellitus (T2DM) in LA countries (Mexico, Brazil, and Argentina).

methodsMOSAIc is a multinational, non-interventional, prospective, observational study aiming to identify the patient-, physician-, and healthcare-based factors affecting insulin intensification. Eligible patients were ≥18 years, had T2DM, and were treated with insulin for ≥3 months with/without oral antidiabetic drugs (OADs). Demographic, clinical, and psychosocial data were collected at baseline and regular intervals during the 24-month follow-up period. This paper however, focuses on baseline data analysis. The association between glycated hemoglobin (HbA1c) and selected covariates was assessed.

resultsA trend toward a higher level of HbA1c was observed in the LA versus non-LA population (8.40 ± 2.79 versus 8.18 ± 2.28; p ≤ 0.069). Significant differences were observed in clinical parameters, treatment patterns, and patient-reported outcomes in LA compared with the rest of the cohorts and between Mexico, Brazil, and Argentina. Higher number of insulin injections and lower number of OADs were used, whereas a lower level of knowledge and a higher level of diabetes-related distress were reported in LA. Covariates associated with HbA1c levels included age (-0.0129; p < 0.0001), number of OADs (0.0835; p = 0.0264), higher education level (-0.2261; p = 0.0101), healthy diet (-0.0555; p = 0.0083), self-monitoring blood glucose (-0.0512; p = 0.0033), hurried communication style in the process of care (0.1295; p = 0.0208), number of insulin injections (0.1616; p = 0.0088), adherence (-0.1939; p ≤ 0.0104), and not filling insulin prescription due to associated cost (0.2651; p = 0.0198).

conclusionMOSAIc baseline data showed that insulin intensification in LA is not optimal and identified several conditions that significantly affect attaining appropriate HbA1c values. Tailored public health strategies, including education, should be developed to overcome such barriers. Trial Registration NCT01400971.

Indexed as

Diabetes educationDiabetes knowledgeDiabetes self-care managementInsulin treatmentLatin AmericaObservational studyPsychological impactQuality of careType 2 diabetes

Identifiers

PMID27453733
PMCPMC4957288
OpenAlexW2487373613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.